We are a team of young and eclectic scientists interested in exploiting gene-engineering tools to study biological functions and solve problems with a direct impact on human health. We exploit a variety of cutting-edge gene editing technologies (CRISPR/Cas, TALEN, ZFN, base editors, and epigenetic transcriptional regulators) to develop new therapeutic strategies for inherited and oncologic diseases. We couple advanced molecular and cell biology approaches, such as viral vectors design, chimeric antigen receptors (CAR), next generation sequencing and ex vivo manipulation of stem cells and primary lymphocytes, with suitable preclinical models of disease to develop novel therapeutics based on precision medicine.